Multiple factors affecting perioperative antibiotherapy in minimally invasive lung surgery: a retrospective...

During the perioperative period, empiric antibiotic escalation therapy is not uncommon, leading to longer postoperative hospital stay and higher medical expenses. However, few systematic studies have investigated this issue. In this case-control study, we explored the factors affecting empiric antibiotic escalation therapy after minimally invasive lung surgery during hospitalization, with the aim to enhance recovery after surgery and rational use of antibiotics.

The data of patients who underwent minimally invasive lung surgery at our center from January 2019 to December 2020 were collected from the hospital information system (HIS). A total of 1,360 cases were identified based on the inclusion and exclusion criteria. These patients were divided into 2 groups: group A (n=825), in which patients did not receive antibiotic escalation therapy after surgery; and group B (n=535), in which patients received empiric antibiotic escalation therapy after surgery. A logistic regression model was used to analyze the influencing factors of empiric antibiotherapy escalation during postoperative hospitalization.

Compared with group A, group B had significantly longer postoperative hospital stay (5.05±2.78 vs. 4.49±2.24 days, P<0.001) and slightly higher average total hospitalization costs (74,080.85±23,796.51 vs. 71,798.09±21,307.26 yuan, P=0.067). Multivariate analysis showed that the statistically significant factors included history of secondary lung surgery [odds ratio (OR): 3.267; 95% confidence interval (CI): 1.305-8.178; P=0.011], preoperative hemoglobin A1c (HbA1c) ≥6.5% (OR: 1.603; 95% CI: 1.143-2.249; P=0.006), postoperative fever of unknown origin [temperature (T) >38 ℃; OR: 2.494; 95% CI: 1.321-4.708; P=0.005], postoperative hypoalbuminemia (intravenous albumin administration for ≥2 days; OR: 14.125; 95% CI: 1.777-112.282; P=0.012).

Multivariate analysis showed that history of secondary lung surgery, preoperative HbA1c ≥6.5%, postoperative fever of unknown origin (T >38 ℃), and postoperative hypoalbuminemia (<35 g/L and intravenous albumin administration ≥2 days) were the independent risk factors for empiric antibiotic escalation therapy after minimally invasive lung surgery. For preoperative risk factors, further cohort studies should be conducted to explore better intervention indicators or measures. For postoperative risk factors, perioperative dynamic monitoring of procalcitonin can guide the rational use of antibiotics, reduce the risk of drug resistance and hospitalization cost.